Model Can Accurately Predict Future Lung Cancer Risk From Low-Dose CT

WEDNESDAY, Jan. 18, 2023 (HealthDay News) -- A deep learning model can accurately predict future lung cancer risk from a single low-dose computed tomography (LDCT) scan, according to a study published online Jan. 12 in the Journal of Clinical Oncology.
Peter G. Mikhael, from the Massachusetts Institute of Technology in Cambridge, and colleagues developed a model called Sybil using LDCT from the National Lung Screening Trial (NLST), which requires only one LDCT and does not require clinical data or radiologist annotations. Sybil was validated in three independent datasets: 6,282 LDCTs from NLST participants; 8,821 LDCTs from Massachusetts General Hospital (MGH); and 12,280 LDCTs from Chang Gung Memorial Hospital (CGMH).
The researchers found that for lung cancer prediction at one year, Sybil achieved areas under the receiver operating characteristic curve of 0.92, 0.86, and 0.94 on the NLST, MGH, and CGMH external validation sets, respectively. Over six years, the concordance indices were 0.75, 0.81, and 0.80 for NLST, MGH, and CGMH, respectively.
"In our study, Sybil was able to detect patterns of risk from the LDCT that were not visible to the human eye," a coauthor said in a statement. "We're excited to further test this program to see if it can add information that helps radiologists with diagnostics and sets us on a path to personalize screening for patients."
Several authors disclosed financial ties to the pharmaceutical, software, and publishing industries; one author holds a patent related to body composition analysis on computed tomography scans.
Related Posts
AHA: Other Defibrillation Strategies Studied for Refractory V-Fib
WEDNESDAY, Nov. 9, 2022 (HealthDay News) -- For patients with refractory...
Mood Swings, Memory Troubles: Minding the Mental Toll of Menopause
WEDNESDAY, Dec. 21, 2022 (HealthDay News) -- Menopause and the years before it...
Moderna afirma que su vacuna contra la COVID funciona bien en los niños de 6 a 11 años
LUNES, 25 de octubre de 2021 (HealthDay News) -- Moderna anunció el lunes que su...
Health Highlights: April 15, 2022
FDA approves first breath test for COVID: The results are delivered within three...